Atrial Fibrillation Course 1: Overview, Initial Evaluation, and Thromboembolic Prevention


Atrial Fibrillation Course 1: Overview, Initial Evaluation, and Thromboembolic Prevention Banner



Date & Location
Saturday, August 31, 2024, 12:00 AM - Saturday, August 30, 2025, 12:00 AM

Target Audience
Specialties - Advanced Practice Professionals, Cardiology, Cardiovascular Disease , Family Medicine, Internal Medicine, Neurology
Professions - Non-Physician, Nurse, Pharmacist, Pharmacy Technician, Physician

Overview

The Division of Continuing Education in Healthcare Professions at IU School of Medicine has partnered with IU eLearning and Design Services to develop and deliver online courses. With the guidance of the Cardiovascular Institute of IU Health, this course will provide the participants with practice guidance in specific treatment goals of atrial fibrillation- classification of atrial fibrillation skills in identifying progression as a disease, initial patient assessment, prevention of stroke, rate control vs rhythm control, attempts to cure, and risk factor modification and monitoring. 


Objectives
At the conclusion of this activity, participants should be able to:

  1. Recognize the electrocardiographic findings of atrial fibrillation, enabling the correct diagnosis and differentiation from other atrial arrhythmias
  2. Understand the pathophysiology and progression of atrial fibrillation.
  3. Identify various symptoms of atrial fibrillation and use screening tools appropriately.
  4. Utilize precise terminology to classify the stages and types of atrial fibrillation based on the most recent guidelines.
  5. Provide a comprehensive evaluation for the optimal management of AF patients.
  6. Employ available decision-making tools to assess the risks and benefits of anticoagulation therapy and select an appropriate stroke prevention strategy.

Registration

Access the Course:

Visit the IUSM CEHP Specialized Education website using the link below.

https://medicine.iu.edu/continuing-education/specialized/atrial-fibrillation

 


Accreditation
 
In support of improving patient care, Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Nurses
Indiana University School of Medicine designates this activity for a maximum of 3.0 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Physicians
Indiana University School of Medicine designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Pharmacists
Indiana University School of Medicine designates this activity for 3.0 ACPE contact hours. Pharmacists should only claim credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Disclosure Summary

Indiana University School of Medicine (IUSM) policy ensures that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all financial relationships with any ineligible companies so that IUSM may identify and mitigate any conflicts of interest prior to the activity. All educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor. 

There are no relevant financial relationship(s) with ineligible companies for anyone who was in control of the content of this activity, except:  

Dr. Mithilesh Das has disclosed Consulting Fee from Johnson and Johnson. 

All of the relevant financial relationships listed for these individuals have been mitigated. 

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

 Commercial Support

This activity is supported by an educational grant from Boston Scientific, Biosense- Webster and Bristol Myers Squibb and Pfizer Alliance

References:

Module 1 

  1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
  2. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
  3. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142-7.
  4. Deshmukh A, Iglesias M, Khanna R, Beaulieu T. Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillation. Heart Rhythm O2. 2022;3(5):577-86.

Module 2

  1. Sposato LA, Chaturvedi S, Hsieh CY, Morillo CA, Kamel H. Atrial Fibrillation Detected After Stroke and Transient Ischemic Attack: A Novel Clinical Concept Challenging Current Views. Stroke. 2022;53(3):e94-e103.
  2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
  3. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 2015;131(25):2176-84.
  4. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754-832.
  5. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017;19(10):1589-623.
  6. Force USPST, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(4):360-7.
  7. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102.
  8. Christophersen IE, Yin X, Larson MG, Lubitz SA, Magnani JW, McManus DD, et al. A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J. 2016;178:45-54.
  9. Lin JY, Larson J, Schoenberg J, Sepulveda A, Tinker L, Wheeler M, et al. Serial 7-Day Electrocardiogram Patch Screening for AF in High-Risk Older Women by the CHARGE-AF Score. JACC Clin Electrophysiol. 2022;8(12):1523-34.
  10. Segan L, Canovas R, Nanayakkara S, Chieng D, Prabhu S, Voskoboinik A, et al. New-onset atrial fibrillation prediction: the HARMS2-AF risk score. Eur Heart J. 2023;44(36):3443-52.
  11. Chung MK, Refaat M, Shen W-K, Kutyifa V, Cha Y-M, Biase LD, et al. Atrial Fibrillation. Journal of the American College of Cardiology. 2020;75(14):1689-713.
  12. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478-86.
  13. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
  14. Li KHC, White FA, Tipoe T, Liu T, Wong MC, Jesuthasan A, et al. The Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review. JMIR Mhealth Uhealth. 2019;7(2):e11606.
  15. Mannhart D, Lischer M, Knecht S, Lavallaz JdFd, Strebel I, Serban T, et al. Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation. JACC: Clinical Electrophysiology. 2023;9(2):232-42.
  16. Sanders P, Purerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B, et al. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. Heart Rhythm. 2016;13(7):1425-30.

Module 3

  1. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10):1455-90.
  2. El-Armouche A, Boknik P, Eschenhagen T, Carrier L, Knaut M, Ravens U, et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation. 2006;114(7):670-80.
  3. Bizhanov KA, capital A CKB, Baimbetov AK, Sarsenbayeva AB, Lyan E. Atrial fibrillation: Epidemiology, pathophysiology, and clinical complications (literature review). J Cardiovasc Electrophysiol. 2023;34(1):153-65.
  4. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-66.
  5. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124(20):2264-74.
  6. Elliott AD, Verdicchio CV, Mahajan R, Middeldorp ME, Gallagher C, Mishima RS, et al. An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial. JACC Clin Electrophysiol. 2023;9(4):455-65.
  7. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
  8. Zhang S, Zhuang X, Lin X, Zhong X, Zhou H, Sun X, et al. Low-Carbohydrate Diets and Risk of Incident Atrial Fibrillation: A Prospective Cohort Study. J Am Heart Assoc. 2019;8(9):e011955.
  9. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol. 2010;55(21):2319-27.
  10. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, et al. Ideal Blood Pressure in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018;72(11):1233-45.
  11. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
  12. Parkash R, Wells GA, Sapp JL, Healey JS, Tardif JC, Greiss I, et al. Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]). Circulation. 2017;135(19):1788-98.
  13. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Levy P, et al. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review. JAMA Cardiol. 2018;3(6):532-40.

Module 4

  1. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
  2. Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023;20(6):404-17.
  3. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73.
Module 5
  1. Piccini JP, Sr., Fonarow GC. Preventing Stroke in Patients With Atrial Fibrillation-A Steep Climb Away From Achieving Peak Performance. JAMA Cardiol. 2016;1(1):63-4.
  2. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
  3. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
  4. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.
  5. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100.
  6. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713-9.
  7. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401.
  8. Di Biase L, Lakkireddy DJ, Marazzato J, Velasco A, Diaz JC, Navara R, et al. Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(1):82-108.

Additional Information

For questions about accessibility or to request accommodations please contact project manager, Breann Bauer at [email protected]. One-week advance notice will allow us to provide seamless access. Please ensure to specify the accommodations you need in order to participate.


Credits
AMA PRA Category 1 Credits™ (3.00 hours), ABIM MOC Part 2 (3.00 hours), ACPE Contact Hours (3.00 hours), ANCC Contact Hours (3.00 hours), Non-Physician Attendance (3.00 hours)